Research Analysts’ Weekly Ratings Updates for Liquidia (LQDA)

Liquidia (NASDAQ: LQDA) recently received a number of ratings updates from brokerages and research firms:

• 8/13/2026 – Liquidia had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $106.00 price target on the stock.
• 8/13/2026 – Liquidia had its price target raised by Wells Fargo & Company from $62.00 to $108.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Liquidia was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/13/2026 – Liquidia had its price target raised by Bank of America Corporation from $79.00 to $92.00. They now have a “neutral” rating on the stock.
• 8/12/2026 – Liquidia had its price target raised by BTIG Research from $109.00 to $111.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Liquidia had its price target raised by Needham & Company LLC from $70.00 to $110.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Liquidia was downgraded by Lifesci Capital from “outperform” to “hold”. They now have a $90.00 price target on the stock.
• 7/24/2026 – Liquidia was given a new $130.00 price target by Royal Bank Of Canada.
• 7/24/2026 – Liquidia was given a new $36.00 price target by HC Wainwright.
• 7/24/2026 – Liquidia was given a new $129.00 price target by Piper Sandler.
• 7/24/2026 – Liquidia was given a new $130.00 price target by Stephens.
• 7/23/2026 – Liquidia had its price target raised by HC Wainwright from $75.00 to $130.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Liquidia had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/29/2026 – Liquidia had its “neutral” rating reaffirmed by Bank of America Corporation. They now have a $79.00 price target on the stock, up from $64.00.
• 6/27/2026 – Liquidia was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/22/2026 – Liquidia had its price target raised by BTIG Research from $59.00 to $109.00. They now have a “buy” rating on the stock.

Insider Activity

In other Liquidia news, CAO Dana Boyle sold 1,600 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $87.53, for a total transaction of $140,048.00. Following the sale, the chief accounting officer directly owned 167,919 shares in the company, valued at $14,697,950.07. This represents a 0.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,185 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $84,739.35. Following the completion of the transaction, the insider directly owned 65,947 shares of the company’s stock, valued at $4,715,869.97. This represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,731,861 shares of company stock worth $121,514,862 over the last 90 days. Company insiders own 25.60% of the company’s stock.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).